Skip to main
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 46%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Holdings is an innovative healthcare company with a recent acquisition that is expected to drive revenue and market share growth, combined with a strong financial performance. Despite concerns about competition and reimbursement changes, the company has a positive outlook due to plans for expansion and partnerships, particularly with their Zio MCT product. Raised revenue guidance and positive analyst recommendations further support a favorable outlook for the company.

Bears say

iRhythm Holdings is a digital healthcare company that has shown strong revenue growth and profitability potential thanks to its innovative device-based technology and strong market position in the extended-wear cardiac monitoring industry. However, potential risks, such as lower commercial reimbursement rates, competition from existing players, potential FDA warning letters, and delays in key product launches, may hinder the company's growth and impact its profitability in the long run. Further growth drivers, including expansion into the asymptomatic AF space and international markets, exist, but may take longer to materialize than currently anticipated.

iRhythm Technologies (IRTC) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 46% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 13 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $173.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $173.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.